Compare InMode Ltd (INMD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Twist Bioscience Corp — how do they compare? InMode Ltd trades at $15.38 (market cap $882.90M), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 6.2× InMode Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| INMD | TWST | |
|---|---|---|
Market Cap | $882.90M | $5.45B |
Sector | Technology | Health |
52-Week High | $16.62 | $102.88 |
52-Week Low | $12.76 | $24.16 |
Enterprise Value | $350.57M | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal and strong profitability metrics including a 77.84% gross margin and 23.27% net margin. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and Q2 2026 revenue guidance of $95.2M-$95.4M. The stock shows robust cash flow generation with $147.21M net cash flow in 2025.
The outlook is mixed with solid fundamentals and acquisition interest providing upside potential, but Q1 2026 earnings miss and ongoing securities fraud investigations pose risks. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism amid corporate developments.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
